[HTML][HTML] Intermediate vancomycin susceptibility in a community-associated MRSA clone
CJ Graber, MK Wong, HA Carleton… - Emerging infectious …, 2007 - ncbi.nlm.nih.gov
CJ Graber, MK Wong, HA Carleton, F Perdreau-Remington, BL Haller, HF Chambers
Emerging infectious diseases, 2007•ncbi.nlm.nih.govWe describe a case of treatment failure caused by a strain of USA300 community-associated
methicillin-resistant Staphylococcus aureus (MRSA) with intermediate susceptibility to
vancomycin and reduced susceptibility to daptomycin. The strain was isolated from the bone
of a 56-year-old man with lumbar osteomyelitis after a 6-week treatment course of
vancomycin for catheter-associated septic thrombophlebitis.
methicillin-resistant Staphylococcus aureus (MRSA) with intermediate susceptibility to
vancomycin and reduced susceptibility to daptomycin. The strain was isolated from the bone
of a 56-year-old man with lumbar osteomyelitis after a 6-week treatment course of
vancomycin for catheter-associated septic thrombophlebitis.
Abstract
We describe a case of treatment failure caused by a strain of USA300 community-associated methicillin-resistant Staphylococcus aureus (MRSA) with intermediate susceptibility to vancomycin and reduced susceptibility to daptomycin. The strain was isolated from the bone of a 56-year-old man with lumbar osteomyelitis after a 6-week treatment course of vancomycin for catheter-associated septic thrombophlebitis.
ncbi.nlm.nih.gov
